Primary central nervous system posttransplant lymphoproliferative disease: An uncommon diagnostic dilemma

Nephrology (Carlton). 2016 Jun;21(6):528. doi: 10.1111/nep.12626.

Authors

Dov Degen¹, John Kanellis², Peter Hughes³, David Barit⁴, Francesco Ierino⁵

Affiliations

¹ Department of Nephrology, Austin Health, Melbourne, Victoria, Australia. dovdegen@optusnet.com.au.
² Department of Nephrology, Monash Medical Centre, Melbourne, Victoria, Australia.
³ Department of Nephrology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
⁴ Department of Nephrology, Northern Hospital, Melbourne, Victoria, Australia.
⁵ Department of Nephrology, Austin Health, Melbourne, Victoria, Australia.

PMID: 27188412
DOI: 10.1111/nep.12626

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Antiviral Agents / therapeutic use
Biopsy
Brain Neoplasms / diagnosis*
Brain Neoplasms / drug therapy
Brain Neoplasms / virology
Central Nervous System Viral Diseases / diagnosis*
Central Nervous System Viral Diseases / drug therapy
Central Nervous System Viral Diseases / virology
Diabetes Mellitus, Type 1 / complications
Diabetes Mellitus, Type 1 / surgery*
Diabetic Nephropathies / etiology
Diabetic Nephropathies / surgery*
Diagnosis, Differential
Diagnostic Errors
Epstein-Barr Virus Infections / diagnosis*
Epstein-Barr Virus Infections / drug therapy
Epstein-Barr Virus Infections / virology
Humans
Immunosuppressive Agents / therapeutic use
Kidney Transplantation / adverse effects*
Lymphoma, Large B-Cell, Diffuse / diagnosis*
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / virology
Magnetic Resonance Imaging
Male
Pancreas Transplantation / adverse effects*
Predictive Value of Tests
Time Factors
Treatment Outcome

Substances

Antiviral Agents
Immunosuppressive Agents